ReviewBrain pathology (Zurich, Switzerland)2005
Immunological and anti-chaperone therapeutic approaches for Alzheimer disease.
Review in Brain pathology (Zurich, Switzerland), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 54 citations in OpenAlex.
- Targeting the awry Aβ pathway in Alzheimer's disease: hype and hurdles.Inflammopharmacology · 2025Review
- Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy.The Journal of pharmacology and experimental therapeutics · 2025Review
- Recent Trends in Active and Passive Immunotherapies of Alzheimer's Disease.Antibodies (Basel, Switzerland) · 2023Review
- Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.Immunology · 2021Review
- Protective effect of 2-dodecyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione, isolated from Averrhoa carambola L., against Aβ1-42-induced apoptosis in SH-SY5Y cells by reversing Bcl-2/Bax ratio.Psychopharmacology · 2021Article
- Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease.Frontiers in synaptic neuroscience · 2020Review
- Bacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloid.Aging · 2016Article
- Developing therapeutic vaccines against Alzheimer's disease.Expert review of vaccines · 2016Review
- Review
- Review
- Immunotherapy for Alzheimer's disease.Biochemical pharmacology · 2014Review
- Novel immunological approaches for the treatment of Alzheimer's disease.Zhongguo xian dai shen jing ji bing za zhi · 2014Article
- A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta.Neural regeneration research · 2013Article
- Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's disease.Human vaccines & immunotherapeutics · 2013Article
- New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.British journal of clinical pharmacology · 2012Review
- Could immunomodulation be used to prevent prion diseases?Expert review of anti-infective therapy · 2012Article
- Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease.Journal of neuroimmunology · 2012Article
- Immunomodulation for prion and prion-related diseases.Expert review of vaccines · 2010Review
- Murine models of Alzheimer's disease and their use in developing immunotherapies.Biochimica et biophysica acta · 2010Review
- Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Brain structure & function · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer disease (AD) is the most common cause of dementia. Currently available therapies only provide symptomatic relief. A number of therapeutic approaches are under development that aim to increase the clearance of brain Abeta peptides. These include immune mediated clearance of Abeta and the inhibition of the interaction between Abeta and its pathological chaperones. Both active and passive immunization has been shown to have robust effects in transgenic mouse models of AD on amyloid reduction and behavioral improvements. However, a human trial of active immunization has been associated with significant toxicity in a minority of patients. New generation vaccines are being developed which likely will reduce the potential for cell-mediated toxicity. In addition, the recent development of anti-chaperone therapy opens a new therapeutic avenue which is unlikely to be associated with toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.